Nikolai Klebanov, MD
Dermatology · Beverly, MANPI 1386202158
Payments from drug & device makers
Across 27 payments — averaging $190.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene (suzhou) Co., Ltd.$3K
- E.r. Squibb & Sons, L.L.C.$755
- AbbVie$316
- UCB, Inc.$218
- Boehringer Ingelheim$208
- Johnson & Johnson$205
- plus $605 from 5 others
What the payments were for
- Consulting fees$2,85055%
- Food & beverage$2,21043%
- Education$952%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene (suzhou) Co., Ltd. | 3 | $2,850 |
| E.r. Squibb & Sons, L.L.C. | 10 | $755 |
| AbbVie | 3 | $316 |
| UCB, Inc. | 2 | $218 |
| Boehringer Ingelheim | 2 | $208 |
| Johnson & Johnson | 2 | $205 |
| Dermavant Sciences, Inc. | 1 | $148 |
| Galderma Laboratories, L.p. | 1 | $147 |
| Biofrontera Inc. | 1 | $124 |
| Arcutis Biotherapeutics, Inc. | 1 | $121 |
| LEO Pharma Inc. | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,155 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 17 | $81,771 |
| Dupixent PenDupilumab | 21 | $77,687 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 84 | $6,020 |
| Tacrolimus | 30 | $4,817 |
| Clobetasol Propionate | 61 | $3,367 |
| Fluorouracil | 56 | $2,973 |
| Ketoconazole | 147 | $2,544 |
| Triamcinolone Acetonide | 173 | $2,423 |
| Metronidazole | 27 | $1,000 |
| Ciclopirox | 18 | $733 |
| Hydroxychloroquine Sulfate | 12 | $524 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 11 | $506 |
| Clindamycin Phosphate | 16 | $408 |
| Hydrocortisone | 46 | $299 |
| Doxycycline Hyclate | 18 | $299 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Beverly
- David GreensteinBeverly$4M
- Lilit GaribyanBeverly$196K
- John HarrisWorcester$17.1M
- Mark AmsterBrighton$5M
- Alexandra KimballBoston$3.7M
- Robert NossaMarstons Mills$2.6M
- Gideon SmithBoston$2.6M
- Victoria KuohungQuincy$1.8M
- Ethan LernerCharlestown$1.7M
- Jeffrey DoverChestnut Hill$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.